Cargando…
Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study
BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. Few studies have been published on the clinical stages of recurrent HCC. AIM: To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) st...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462222/ https://www.ncbi.nlm.nih.gov/pubmed/34621858 http://dx.doi.org/10.12998/wjcc.v9.i27.8020 |
_version_ | 1784572159097569280 |
---|---|
author | Yao, Si-Yang Liang, Bin Chen, Yuan-Yuan Tang, Yun-Tian Dong, Xiao-Feng Liu, Tian-Qi |
author_facet | Yao, Si-Yang Liang, Bin Chen, Yuan-Yuan Tang, Yun-Tian Dong, Xiao-Feng Liu, Tian-Qi |
author_sort | Yao, Si-Yang |
collection | PubMed |
description | BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. Few studies have been published on the clinical stages of recurrent HCC. AIM: To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC. METHODS: The clinicopathological data of 81 patients with recurrent HCC who were admitted to the Hospital of Guangxi Zhuang Autonomous Region from January 2013 to December 2017 were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) Group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence and the median overall survival were compared. RESULTS: The median time to tumor recurrence in groups A, B, and C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them (χ(2) = 70.144, P < 0.05); no statistically significant difference was noted between group A and group B (χ(2) = 2.659, P > 0.05), although there were statistically significant differences between group A and group C and between group B and group C (χ(2 )= 62.110, and 19.972, P < 0.05). The median overall survival in groups A, B, and C were 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them (χ(2 )= 38.949, P < 0.05); there were statistically significant differences between group A and group B, group A and group C, and group B and group C (χ(2 )= 9.577, 37.172, and 7.183, respectively; P < 0.05). CONCLUSION: There are different prognoses in recurrent HCC patients according to the BCLC staging. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC. |
format | Online Article Text |
id | pubmed-8462222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-84622222021-10-06 Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study Yao, Si-Yang Liang, Bin Chen, Yuan-Yuan Tang, Yun-Tian Dong, Xiao-Feng Liu, Tian-Qi World J Clin Cases Retrospective Cohort Study BACKGROUND: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. Few studies have been published on the clinical stages of recurrent HCC. AIM: To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC. METHODS: The clinicopathological data of 81 patients with recurrent HCC who were admitted to the Hospital of Guangxi Zhuang Autonomous Region from January 2013 to December 2017 were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) Group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence and the median overall survival were compared. RESULTS: The median time to tumor recurrence in groups A, B, and C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them (χ(2) = 70.144, P < 0.05); no statistically significant difference was noted between group A and group B (χ(2) = 2.659, P > 0.05), although there were statistically significant differences between group A and group C and between group B and group C (χ(2 )= 62.110, and 19.972, P < 0.05). The median overall survival in groups A, B, and C were 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them (χ(2 )= 38.949, P < 0.05); there were statistically significant differences between group A and group B, group A and group C, and group B and group C (χ(2 )= 9.577, 37.172, and 7.183, respectively; P < 0.05). CONCLUSION: There are different prognoses in recurrent HCC patients according to the BCLC staging. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC. Baishideng Publishing Group Inc 2021-09-26 2021-09-26 /pmc/articles/PMC8462222/ /pubmed/34621858 http://dx.doi.org/10.12998/wjcc.v9.i27.8020 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Cohort Study Yao, Si-Yang Liang, Bin Chen, Yuan-Yuan Tang, Yun-Tian Dong, Xiao-Feng Liu, Tian-Qi Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study |
title | Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study |
title_full | Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study |
title_fullStr | Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study |
title_full_unstemmed | Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study |
title_short | Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study |
title_sort | clinical stages of recurrent hepatocellular carcinoma: a retrospective cohort study |
topic | Retrospective Cohort Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462222/ https://www.ncbi.nlm.nih.gov/pubmed/34621858 http://dx.doi.org/10.12998/wjcc.v9.i27.8020 |
work_keys_str_mv | AT yaosiyang clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy AT liangbin clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy AT chenyuanyuan clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy AT tangyuntian clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy AT dongxiaofeng clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy AT liutianqi clinicalstagesofrecurrenthepatocellularcarcinomaaretrospectivecohortstudy |